SRPK1 Eye Drops as a Treatment for Diabetic Retinopathy

साझा करें

संग्रहीत श्रृंखला ("निष्क्रिय फ़ीड" status)

When? This feed was archived on September 02, 2022 19:28 (3M ago). Last successful fetch was on August 02, 2022 20:36 (4M ago)

Why? निष्क्रिय फ़ीड status. हमारे सर्वर निरंतर अवधि के लिए एक वैध डिजिटल ऑडियो फ़ाइल फ़ीड पुनर्प्राप्त करने में असमर्थ थे।

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 335397533 series 2369234
American Physiological Society द्वारा - Player FM और हमारे समुदाय द्वारा खोजे गए - कॉपीराइट प्रकाशक द्वारा स्वामित्व में है, Player FM द्वारा नहीं, और ऑडियो सीधे उनके सर्वर से स्ट्रीम किया जाता है। Player FM में अपडेट ट्रैक करने के लिए ‘सदस्यता लें’ बटन दबाएं, या फीड यूआरएल को अन्य डिजिटल ऑडियो फ़ाइल ऐप्स में पेस्ट करें।

The eyes are the window to the soul, as the old saying goes, but are the eyes also the window to cardiovascular disease? Diabetic retinopathy is a common diabetic microvascular disease and a leading cause of blindness in diabetes patients worldwide. Defects in the blood-retinal barrier caused by increased production of vascular endothelial growth factor-A isoforms promote angiogenesis and permeability. Listen as Consulting Editor Dr. Shawn Bender (University of Missouri, Columbia) interviews first author Dr. Naseeb Malhi (City of Hope National Medical Center), senior author Dr. David Bates (University of Nottingham), and expert Dr. Jerome Breslin (University of South Florida) about the new study by Malhi et al, which investigated whether serine-arginine-rich protein kinase-1 (SRPK1) inhibition can attenuate the pathophysiology of diabetic retinopathy. The authors conducted a combination of mechanistic in vitro studies using human retinal pigment epithelial cells and studies in type 1 diabetic rats to investigate whether SRPK1 is activated in diabetes, and whether an SRPK1 inhibitor (SPHINX31) switches VEGF splicing in diabetic retinopathy to prevent increased vascular permeability into the retina. The novel intervention design of delivering the SRPK1 inhibitor via eyedrop in the authors’ diabetic rat model was used preventatively at the outset of the diabetes phenotype. Does this unique treatment modality offer promise for treating established diabetic retinopathy? Listen and learn.

Naseeb K. Malhi, Claire L. Allen, Elizabeth Stewart, Katherine L. Horton, Federica Riu, Jennifer Batson, Winfried Amoaku, Jonathan C. Morris, Kenton P. Arkill, David O. Bates Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy Am J Physiol Heart Circ Physiol, published May 10, 2022. DOI: 10.1152/ajpheart.00001.2022

117 एपिसोडस